Form D · Hedge Fund
Bregma Capital Life Sciences Fund, LP
San Francisco, CA · CIK 0002152390
Offering snapshot reported Aug 31, 2026 · SEC filing
- Reported sold
- Yet to sell Indefinite offering
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $1M Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 31, 2026 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Pooled investment fund
- Exemptions
- 06b, 3C, 3C.7
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-595945
The recipient disclosed in Item 12 will receive certain placement fees with respect to clients introduced to the Issuer, as disclosed to the applicable clients.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Profor Securities, LLC | 136084 |
Source: Form D, filed Aug 31, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bregma Capital Gp, Llc | Executive |
| Bregma Capital, Lp | Executive |
| Mark E. Karvosky | Executive |
Issuer details
Industry: Pooled Investment Fund (See others in industry)
Address:
224 Presidio Ave
San Francisco, CA, 94115
San Francisco, CA, 94115